Noncontrolling Interest (Tables)

6 Months Ended

Jun. 30, 2024

Noncontrolling Interest [Abstract]

Schedule of Noncontrolling Interest of Stockholders' Equity

The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity is summarized for the periods indicated as follows:

	June 30, 2024
NCI – equity - December 31, 2023	$	29,813
Net loss attributable to NCI		(7,387	)
Impact of subsidiary equity transactions		(2,169	)
Lucid Diagnostics proceeds from issuance of preferred stock Series A-1		5,670
Lucid Diagnostics exchange of preferred stock Series A and Series A-1		(24,294	)
Lucid Diagnostics proceeds from issuance of preferred stock Series B and Series B-1		55,919
Lucid Diagnostics deemed dividend on preferred stock		(7,496	)
Lucid Diagnostics issuance of common stock for settlement of vendor service agreement		401
Lucid Diagnostics 2018 Equity Plan stock option exercise		4
Lucid Diagnostics Employee Stock Purchase Plan Purchase		353
Conversion of Lucid Diagnostics common stock for Senior Secured Convertible Debt		2,541
Stock-based compensation expense - Lucid Diagnostics 2018 Equity Plan		1,850
Stock-based compensation expense - Veris Health 2021 Equity Plan		98
NCI – equity - June 30, 2024	$	55,303

Schedule of Net Loss Attributable to Common Stockholders

Series B Convertible Preferred Stock Issuance and Series A/A-1 Exchange Offer	March 13, 2024
Fair Value - 44,285 shares of Series B Preferred Stock issued	$	44,285
Less: Fair value related to newly issued Series B Preferred Stock (of 12,495 shares)		(12,495	)
Less: Carrying value related to Series A and Series A-1 Preferred Stock Exchanged for Series B Preferred Stock (of 24,295 shares)		(24,294	)
Deemed Dividend Charged to Accumulated Deficit	$	7,496